Reiterating the expense forecast indicates stability in Vir Biotechnology's financial planning and operational execution. This transparency may reassure investors about the company's management and strategic direction. However, the impact on the stock price is likely neutral in the short term as this reaffirmation does not introduce new information but confirms previous expectations.